2025年ASCO中国之声:突破耐药、填补空白 科伦博泰生物芦康沙妥珠单抗展现EGFR突变非小细胞肺癌治疗前景

每日经济新闻
Jun 04

科伦博泰生物(HK06990)股价再创新高,今日盘中触及363港元/股。  消息面上,在近日举行的2025年美国临床肿瘤学会(ASCO)年会上,科伦博泰的TROP2 ADC芦康沙妥珠单抗治疗EGFR突变晚期非小细胞肺癌(NSCLC)的多项研究数据重磅公布,其临床价值引发学界广泛关注。  突破耐药瓶颈,为EGFR-TKI耐药患者开辟新径   在亚洲人群中,EGFR基因突变是肺癌(尤其是肺腺癌)最常见...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10